Joseph Thome
Stock Analyst at TD Cowen
(1.75)
# 3,395
Out of 5,140 analysts
19
Total ratings
50%
Success rate
-1.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $75.56 | -16.62% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $7.99 | +25.16% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $93.27 | +1.85% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $86.04 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $32.29 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $469.77 | -14.85% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $26.40 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $33.85 | +0.44% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $4.01 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi Therapeutics | Initiates: Outperform | n/a | $1.63 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.00 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.09 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $189.10 | -31.25% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.03 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.30 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $75.56
Upside: -16.62%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $7.99
Upside: +25.16%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $93.27
Upside: +1.85%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $86.04
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $32.29
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $469.77
Upside: -14.85%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $26.40
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $33.85
Upside: +0.44%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $4.01
Upside: -
Metagenomi Therapeutics
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.63
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.00
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.09
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $189.10
Upside: -31.25%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.03
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.30
Upside: -